Quantitative Immunopeptidomics Drives Target Discovery & Rational Antibody Design for T Cell Engagers
- Exploring how high-sensitivity, targeted immunopeptidomics enable direct detection and detailed characterization of drug-modified (haptenated) peptide–MHC complexes, informing the rational design of bispecific T cell engagers with cross-HLA reactivity
- Outlining how the quantitative profiling of amplified MHC-I targets defines the therapeutic window and guides engineering of T cell engagers against canonical, mutation-agnostic epitopes such as pan-KRAS amplification
- Integrating immunoproteomics-driven target validation with antibody engineering to accelerate the development of next-generation T cell engagers, exemplified by programs targeting mutant KRAS, KRAS amplification, and p53 mutants